LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement

LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.